Regeneus Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
7,523.20
6,606.50
3,573.90
3,270.60
5,184.60
Depreciation, Depletion & Amortization
333.70
404.70
350.80
326.20
348.00
Other Funds
-
-
-
246.70
1,354.40
Funds from Operations
5,033.60
5,617.90
3,238.60
3,595.40
4,815.30
Changes in Working Capital
1,205.70
305.40
985.40
8.20
568.30
Net Operating Cash Flow
6,239.30
5,923.40
2,253.20
3,587.20
4,247.00
Capital Expenditures
1,175.90
207.90
249.70
149.90
151.00
Sale of Fixed Assets & Businesses
-
8.20
18.80
9.60
-
Purchase/Sale of Investments
697.50
460.40
-
87.10
-
Net Investing Cash Flow
1,873.30
260.80
230.90
227.50
151.00
Net Financing Cash Flow
10,209.40
6,167.90
-
246.70
1,354.40
Net Change in Cash
2,096.80
505.30
2,484.10
3,606.50
3,043.60
Free Cash Flow
7,414.00
6,116.40
2,502.90
3,437.20
4,398.00
Change in Capital Stock
10,209.40
6,167.90
-
-
-

About Regeneus

View Profile
Address
25 Bridge Street
Pymble New South Wales (NSW) 2073
Australia
Employees -
Website http://www.regeneus.com.au
Updated 07/08/2019
Regeneus Ltd. is regenerative medicine company. It develops and commercializes innovative cell-based therapies to address unmet medical needs in human and veterinary health. The company was founded by Ben Herbert and Graham Vesey on August 14, 2007 and is headquartered in Pymble, Australia.